Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Duloxetine blocks psychostimulant effects

Sep. 5, 2011

Randomized phase II trial evaluates alfuzosin in women with voiding dysfunction

Sep. 5, 2011

Preclinical data presented on dual orexin OX1/OX2 receptor antagonist developed at Merck & Co.

Sep. 5, 2011

Gilead discloses results from evaluation of HCV NS3/NS4A inhibitor in healthy volunteers

Sep. 5, 2011

Phase I/II trial assesses everolimus in tuberous sclerosis complex

Sep. 5, 2011

Results from RUBY-1 trial investigating darexaban in acute coronary syndrome reported

Sep. 5, 2011

LIST trial compares long-term effects of imidafenacin and solifenacin in OAB

Sep. 2, 2011

Merck & Co. presents new gamma-secretase inhibitor as clinical candidate in Alzheimer's disease

Sep. 2, 2011

Phosphodiesterase 5 inhibitor suppresses bladder mechanosensory activity in vivo

Sep. 2, 2011

New 11-beta-HSD1 inhibitor has potent preclinical activity

Sep. 2, 2011

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...